Education
LLM, Universities of Leyden Law School and Utrecht Department of Health Administration, School of Medicine
PhD, University of Amsterdam School of Medicine and Department of Science Policy
-
1994
Investigator Award in Health Policy Research -
1987
International Fellow, Council on Health Care Technology -
1987
The Querido-Award for the most promising young investigator in public health, the National Foundation for Health Promotion and Disease Prevention (Praeventiefonds)
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Gelijns did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.